The European Society of Cardiology has introduced groundbreaking guidelines for managing cardiovascular disease (CVD) in patients with chronic kidney disease (CKD), developed in collaboration with the European Renal Association. These guidelines, released online in the European Heart Journal, will also be showcased at the upcoming ESC Congress 2026 on August 29.
Understanding Chronic Kidney Disease
Chronic kidney disease is characterized by structural or functional abnormalities in the kidneys lasting at least three months, leading to significant health implications. In Europe alone, approximately 100 million individuals are affected by CKD, which places them at a heightened risk for various cardiovascular diseases.
The interplay between CKD and CVD is particularly concerning, as CKD can exacerbate cardiovascular issues, leading to premature cardiovascular events and an increased necessity for dialysis. However, advancements in recent years have unveiled effective treatments that can significantly mitigate the risks associated with both conditions.
The Role of Cardiology in CKD Management
Associate Professor Kevin Damman, the Task Force Chair from the University Medical Centre Groningen in the Netherlands, emphasizes the importance of enhancing cardiology’s role in CKD management. Professor William Herrington from the University of Oxford highlights that many CKD patients receive care from cardiologists, and the new guidelines aim to promote kidney function and urine albumin testing among these patients. Enhanced screening can identify at-risk individuals, allowing for tailored treatment strategies for both CKD and CVD.
The ‘STAMP on CKD’ Approach
To streamline the management process, the Task Force introduced the acronym ‘STAMP on CKD,’ signifying:
- Screen: Conducting blood and urine tests to diagnose CKD in all patients with CVD.
- Triage: Accurately assessing risks related to kidney failure and cardiovascular disease using validated scoring systems.
- Address CKD Risk: Early implementation of cost-effective therapies that can slow CKD progression and lower cardiovascular risks.
- Modify CVD Management: Adjusting treatment plans to account for patients whose kidney function may limit the effectiveness of standard medications.
- Plan Health Services: Ensuring healthcare systems are equipped to recognize and treat high-risk patients efficiently.
The initial step of screening involves evaluating patients with CVD for CKD through blood tests that determine glomerular filtration rate and urine tests assessing albumin levels.
Importance of Early Intervention
Early intervention with proven therapies, such as RAS inhibitors and SGLT2 inhibitors, coupled with statin-based treatments, is crucial. Associate Professor Damman notes that these drugs are particularly effective in managing both CKD and CVD.
The guidelines also underscore necessary adjustments to cardiovascular management, especially concerning medications that may not be suitable for patients with impaired kidney function. This consideration is essential for optimizing treatment efficacy and patient safety.
Effective Communication Among Specialties
The guidelines stress the need for coordinated communication between cardiologists and nephrologists to address the complexities associated with CKD. Professor Herrington points out that effective collaboration is vital for managing these intertwined conditions. Involving patients and their families in the multidisciplinary care approach ensures that their preferences and needs are prioritized, enhancing overall care quality.
Empowering Patients Through Knowledge
An accessible version of the guidelines is also available for patients, providing them with the information needed to engage in shared decision-making with healthcare providers. This empowerment is essential for improving patient outcomes and fostering a collaborative healthcare environment.
Conclusion
These new guidelines mark a significant step forward in the integrated management of CVD and CKD, addressing the pressing challenges faced by patients and healthcare systems. By emphasizing screening, early intervention, and collaboration among healthcare providers, the hope is to enhance patient care and reduce the burdens of these chronic conditions on individuals and society alike.
- Key Takeaways:
- Chronic kidney disease and cardiovascular disease are closely linked.
- Early screening and intervention are critical for effective management.
- Collaboration between cardiologists and nephrologists is essential.
- Patient engagement in care decisions can improve outcomes.
- The new guidelines aim to fill existing gaps in evidence and practice.
Read more → www.news-medical.net